Active ingredientPibrentasvirCat. No. P-P105-001CAS 1353900-92-1Family · Pharmaceutical analytical standards
Pibrentasvir
A direct-acting antiviral that blocks the NS5A protein of the hepatitis C virus, approved in 2017 in Europe and the United States in combination with glecaprevir: the therapy is active against all genotypes of the virus. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?The -asvir ending is shared by inhibitors of NS5A, a viral protein needed both to copy the virus's RNA and to assemble new virus particles.
Go to the active ingredient →Active ingredientPibrentasvirCat. No. P-P105-001CAS 1353900-92-1
Isotopically labelledPibrentasvir-d6Cat. No. P-P105-003
ImpurityPibrentasvir Impurity 1Cat. No. P-P105-004CAS 1332356-31-6
ImpurityPibrentasvir Impurity 2Cat. No. P-P105-005CAS 1332357-14-8
ImpurityPibrentasvir Impurity 3Cat. No. P-P105-006CAS 1890114-11-0
ImpurityPibrentasvir Impurity 4Cat. No. P-P105-007CAS 1292836-20-4
ImpurityPibrentasvir Impurity 5Cat. No. P-P105-008No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.